After Dolly: The Promise and Perils of Cloning
Description:
A brave, moral argument for cloning and its power to fight disease.
A timely investigation into the ethics, history, and potential of human cloning from Professor Ian Wilmut, who shocked scientists, ethicists, and the public in 1997 when his team unveiled Dolly―that very special sheep who was cloned from a mammary cell. With award-winning science journalist Roger Highfield, Wilmut explains how Dolly launched a medical revolution in which cloning is now used to make stem cells that promise effective treatments for many major illnesses. Dolly's birth also unleashed an avalanche of speculation about the eventuality of cloning babies, which Wilmut strongly opposes. However, he does believe that scientists should one day be allowed to combine the cloning of human embryos with genetic modification to free families from serious hereditary disease. In effect, he is proposing the creation of genetically altered humans. 20 illustrationsBest prices to buy, sell, or rent ISBN 9780393330267
Frequently Asked Questions about After Dolly: The Promise and Perils of Cloning
The price for the book starts from $7.99 on Amazon and is available from 23 sellers at the moment.
At BookScouter, the prices for the book start at $3.28. Feel free to explore the offers for the book in used or new condition from various booksellers, aggregated on our website.
If you’re interested in selling back the After Dolly: The Promise and Perils of Cloning book, you can always look up BookScouter for the best deal. BookScouter checks 30+ buyback vendors with a single search and gives you actual information on buyback pricing instantly.
As for the After Dolly: The Promise and Perils of Cloning book, the best buyback offer comes from and is $ for the book in good condition.
The After Dolly: The Promise and Perils of Cloning book is in very low demand now as the rank for the book is 3,916,784 at the moment. A rank of 1,000,000 means the last copy sold approximately a month ago.
Not enough insights yet.